Trial Profile

An Open-label, Multicenter Follow-up Study to Collect Long-term Data on Participants From Multiple Bintrafusp Alfa (M7824) Clinical Studies

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 11 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bintrafusp alfa (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Biliary cancer; Carcinoma; Cervical cancer; Cholangiocarcinoma; Gallbladder cancer; Male breast cancer; Non-small cell lung cancer; Periampullary cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions
Acronyms INTR@PID 054
Sponsors EMD Serono Research & Development Institute; Merck KGaA

Most Recent Events

29 Apr 2025 Status changed from active, no longer recruiting to completed.
14 Mar 2024 Planned End Date changed from 20 Jun 2025 to 3 Apr 2025.
14 Mar 2024 Planned primary completion date changed from 20 Jun 2025 to 3 Apr 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com